Prevention of hyperphosphatemia in kidney disorder patients

Details Prevention of hyperphosphatemia in kidney disorder patients Prevention of hyperphosphatemia in kidney disorder patients

1995-07-13

1997-01-28

Spivack, Phyllis G.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

9,10-seco- cyclopentanohydrophenanthrene ring system doai

A61K 3159

Patent

active

055978150

ABSTRACT:
The 19-nor-vitamin D analogs, and particularly 19-nor-1.alpha.,25-dihydroxyvitamin D.sub.2, possess low calcemic and phosphatemic activity while also having the ability to suppress parathyroid hormone (PTH) production. The suppressive effect on PTH secretion of these 19-nor analogs without significant changes in serum calcium or serum phosphorus make them ideal tools for the treatment of secondary hyperparathyroidism in patients having kidney disorders.

REFERENCES:
patent: 5063221 (1991-11-01), Nishii et al.
patent: 5086191 (1992-08-01), Deluca et al.
patent: 5237110 (1993-08-01), Deluca et al.
patent: 5246925 (1993-09-01), Deluca et al.
patent: 5281731 (1994-01-01), Deluca et al.
Lee et al., Abstract Proc. Workshop Vitam. D (1979).

Affiliated with

Also associated with

Rating

Prevention of hyperphosphatemia in kidney disorder patients does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Prevention of hyperphosphatemia in kidney disorder patients, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prevention of hyperphosphatemia in kidney disorder patients will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-941604